{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.7.2.', 'Safety Analysis', '100', '9.8.', 'Pharmacokinetic Analysis', '101', '9.9.', 'Planned Interim Analysis', '101', '9.10.', 'Reporting Deviations from the Statistical Plan', '101', '10.', 'DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS', '102', '11.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '103', '11.1.', 'Protocol Amendments and Protocol Deviations and Violations', '103', '11.1.1.', 'Protocol Amendments', '103', '11.1.2.', 'Protocol Violations', '103', '11.2.', 'Information to Study Personnel', '103', '11.3.', 'Study Monitoring', '104', '11.4.', 'Clinical Product Complaints', '104', '11.4.1.', 'Product Complaint Information Needed from the Investigational Center', '105', '11.4.2.', 'Handling of IMP at the Investigational Center', '105', '11.4.3.', 'Adverse Events or Serious Adverse Events Associated with a Product', 'Complaint', '106', '11.4.4.', 'Documenting a Product Complaint', '106', '11.5.', 'Audit and Inspection', '106', '12.', 'ETHICS', '107', '12.1.', 'Informed Consent/Assent', '107', '12.2.', 'Competent Authorities and Independent Ethics Committees/Institutional', 'Review Boards', '107', '12.3.', 'Confidentiality Regarding Study Patients', '107', '12.4.', 'Declaration of the End of Clinical Study', '108', '12.5.', 'Registration of the Clinical Study', '108', '13.', 'DATA HANDLING, DATA QUALITY CONTROL, AND RECORD', 'KEEPING', '109', '13.1.', 'Data Collection', '109', '13.2.', 'Data Quality Control', '109', '13.3.', 'Archiving of Case Report Forms and Source Documents', '110', '13.3.1.', 'Sponsor Responsibilities', '110', '13.3.2.', 'Investigator Responsibilities', '110', '14.', 'FINANCING AND INSURANCE', '112', '26']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '15.', 'REPORTING AND PUBLICATION OF RESULTS', '113', '16.', 'REFERENCES', '114', '17.', 'SUMMARY OF CHANGES TO PROTOCOL', '116', '17.1.', 'Amendment 01 Dated 22 June 2017', '116', '17.2.', 'Amendment 02 Dated 03 October 2017', '136', '17.3.', 'Amendment 03 Dated 06 November 2017', '164', '17.4.', 'Amendment 04 Dated 13 September 2018', '173', '17.5.', 'Amendment 05 Dated 25 March 2019', '195', 'APPENDIX A. ALLOWED AND DISALLOWED MEDICATIONS', '205', 'APPENDIX B. DISTRIBUTION OF AUC BY WEIGHT CATEGORIES AND', 'CYP2D6 STATUS', '209', 'APPENDIX C. MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW', 'FOR CHILDREN AND ADOLESCENTS', '210', \"APPENDIX D. CHILDREN'S DEPRESSION INVENTORY, SECOND EDITION,\", 'PARENT AND SELF-REPORT PROFILES', '228', \"APPENDIX E. CHILDREN'S COLUMBIA-SUICIDE SEVERITY RATING SCALE\", '236', \"APPENDIX F. CHILDREN'S YALE-BROWN OBSESSIVE-COMPULSIVE SCALE\", '242', 'APPENDIX G. YALE GLOBAL TIC SEVERITY SCALE', '255', 'APPENDIX H.', '264', 'APPENDIX I.', '265', 'APPENDIX J.', '267', 'APPENDIX K.', '268', 'APPENDIX L.', '27']\n\n###\n\n", "completion": "END"}